Lithium related thyroid and parathyroid disease: Updated clinical practice guidelines are needed
Journal of Affective Disorders · 2023
DOI: 10.1016/j.jad.2023.07.037 ↗Kurz gefasst
Leitlinie in der Zeitschrift Journal of Affective Disorders, 2023. Verfasst von Sewon Bann und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology & Metabolism, St. Paul's Hospital & University of British Columbia, Vancouver, British Columbia, Canada. Hauptthemen laut MEDLINE: Thyroid Diseases, Parathyroid Diseases, Practice Guidelines as Topic, Practice Patterns, Physicians'. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 16 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVE: This study aims to estimate the prevalence of and determine physician approaches to the screening and management of lithium-associated thyroid and parathyroid disorders in British Columbia, Canada. METHODS: Serum lithium and thyroid/parathyroid laboratory data were collected retrospectively for patients with lithium levels measured at seven BC hospitals between 2012 and 2021. A mail-out survey about screening and management of thyroid/parathyroid disorders in patients on lithium was sent to the ordering physicians of patients with abnormal results. Three months after, a follow-up questionnaire was sent to respondents, and the original survey was re-sent to non-responders. RESULTS: Of 4917 patients, 1.9 % had PTH (mean 22.33 ± 23.00 pmol/L) and 77.1 % had TSH (mean 3.61 ± 6.69 pmol/L) measured. Of 222 hypercalcemic patients (defined as any serum calcium or ionized calcium above the laboratory reference), 17.6 % had a PTH level measured. From 294 surveys sent to 214 physicians, the overall response rate was 31.6 % (n = 93) with twelve fully completed surveys. All twelve respondents monitored TSH levels every 6-12 months, and eight physicians monitored PTH and/or calcium at variable intervals. Two physicians routinely ordered both thyroid and parathyroid screening laboratory tests. Of the 80 non-respondents, limited patient contact was the most common reason for opting out (n = 27). CONCLUSIONS: Our results suggest biochemical screening for lithium-associated parathyroid disorders is less common than for thyroid disorders. There is insufficient data to determine the true prevalence of lithium-associated thyroid and parathyroid disorders. This highlights the need for updated clinical guidelines for management of lithium-associated thyroid and parathyroid disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology & Metabolism, St. Paul's Hospital & University of British Columbia, Vancouver, British Columbia, Canada.
- Department of Surgery, St. Paul's Hospital & University of British Columbia, Vancouver, British Columbia, Canada.
- Department of Psychiatry, St. Paul's Hospital & University of British Columbia, Vancouver, British Columbia, Canada.
- Department of Pathology & Laboratory Medicine, St. Paul's Hospital & University of British Columbia, Vancouver, Britsh Columbia, Canada.
- Department of Surgery, St. Paul's Hospital & University of British Columbia, Vancouver, British Columbia, Canada. Electronic address: SMWiseman@providencehealth.bc.ca.
Zitieren
APA
Bann, S., Nguyen, A., Gill, S., Raudzus, J., Holmes, D. T., & Wiseman, S. M. (2023). Lithium related thyroid and parathyroid disease: Updated clinical practice guidelines are needed. Journal of Affective Disorders. https://doi.org/10.1016/j.jad.2023.07.037
Vancouver
Bann S, Nguyen A, Gill S, Raudzus J, Holmes DT, Wiseman SM. Lithium related thyroid and parathyroid disease: Updated clinical practice guidelines are needed. Journal of Affective Disorders. 2023. doi:10.1016/j.jad.2023.07.037
BibTeX
@article{Bann2023,
author = {Bann, Sewon and Nguyen, Anne and Gill, Sabrina and Raudzus, Julia and Holmes, Daniel T and Wiseman, Sam M},
title = {Lithium related thyroid and parathyroid disease: Updated clinical practice guidelines are needed},
journal = {Journal of Affective Disorders},
year = {2023},
doi = {10.1016/j.jad.2023.07.037}
}
EUVIMED